PLCG2 Exon-Skipped Variants: Insights into Their Potential Role in Chronic Lymphocytic Leukemia [0.03%]
PLCG2跳跃型变异体：其在慢性淋巴细胞白血病中潜在作用的初步分析
Jialei Qi,Wen Li,Rashmi Priyadharshini Dheenadayalan et al.
Jialei Qi et al.
Bruton tyrosine kinase inhibitors (BTKi) are successful in treatment of chronic lymphocytic leukemia (CLL), yet acquired resistance remains a challenge. In our study, REC-1 cells that acquired resistance to BTKi tirabrutinib by long-term tr...
Prognostic factors and survival outcomes in relapsed/refractory aggressive B-cell lymphomas treated with epcoritamab [0.03%]
靶向CD19/CD3的双特异性抗体epcoritamab治疗复发/难治侵袭性B细胞淋巴瘤的预后因素和生存分析
Allison M Bock,Lei Feng,Ayushi Chauhan et al.
Allison M Bock et al.
Epcoritamab is an FDA-approved bispecific antibody for relapsed/refractory (R/R) large B-cell lymphomas (LBCLs). Real-world outcomes and safety data remain limited. We analyzed 157 adult patients with R/R aggressive BCLs who received epcori...
Donor-Specific Transplant Outcomes from BMTCTN 1702: A Multi-Center Prospective Biological-Assignment Trial [0.03%]
BMTCTN 1702多中心前瞻性生物赋值试验的供者特异性移植结局
Asad Bashey,Brent R Logan,LaQuisa C Hill et al.
Asad Bashey et al.
Newer approaches to control alloreactivity may produce similar transplant outcomes using HLA-mismatched donors versus HLA-matched unrelated donors. However, prospective comparisons are lacking. BMT CTN 1702 used a donor search prognosis sco...
Sirolimus for Refractory/relapsed Warm Autoimmune Hemolytic Anemia and Evans' syndrome: A Prospective Study [0.03%]
西罗莫司治疗难治/复发的温抗体自身免疫性溶血性贫血和Evans综合征：一项前瞻性研究
Qi Wang,Ziwei Liu,Chen Yang et al.
Qi Wang et al.
Effective therapeutic options remain limited for adults with relapsed or refractory (R/R) warm autoimmune hemolytic anemia (wAIHA) and Evans syndrome (ES). We conducted a prospective, single-center, open-label clinical trial to evaluate the...
Plant-based whole-food diets are feasible during auto-HCT and are associated with dose-dependent microbiome modulation [0.03%]
基于植物的全食饮食在自体造血干细胞移植期间是可行的，并且与剂量依赖性微生物组调节相关
Katherine Ueland,Taara Elahi,Mary Rasmussen et al.
Katherine Ueland et al.
Plant-based whole foods may represent a tractable approach to mitigating microbiome disruption and improving outcomes in patients undergoing auto-HCT for multiple myeloma, a population in whom intestinal dysbiosis has been linked with infer...
CRISPR application in hematological disorders: from bench to bedside [0.03%]
基于CRISPR的血液系统疾病治疗研究：从实验室到临床
Francesco Ladisa,Eugenio Morelli,Debora Soncini et al.
Francesco Ladisa et al.
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas genome editing has advanced from an experimental tool to a clinically validated therapeutic platform in hematology. Landmark successes in inherited blood diseases includ...
Arnon Nagler
Arnon Nagler
HMA+VEN triplet regimens for the initial treatment of AML in adults (PRO) [0.03%]
成人急性髓系白血病初始治疗的HMA+VEN三联方案(PRO)
Courtney D DiNardo,Curtis A Lachowiez
Courtney D DiNardo
Hematologic Responses Achieved with Luspatercept in Higher-Risk Myelodysplastic Syndromes [0.03%]
Luspatercept诱导的较高风险骨髓增生异常综合征患者的血液学反应
Daniel Leonard,David A Sallman,Kelly Pugh et al.
Daniel Leonard et al.
HLHRUXO: A prospective trial of a ruxolitinib-containing regimen for children with hemophagocytic lymphohistiocytosis [0.03%]
HLHRUXO方案治疗儿童噬血细胞综合征的前瞻性研究
Lauren K Meyer,Kristen Ryan,John C Panetta et al.
Lauren K Meyer et al.
Hemophagocytic lymphohistiocytosis (HLH) is a severe hyperinflammatory syndrome characterized by excessive immune cell activation and hypersecretion of inflammatory cytokines, many of which signal via the Janus kinases (JAKs). Preclinical s...